JHN CQ 20190715 HFrEFに対する強心薬使用...
Transcript of JHN CQ 20190715 HFrEFに対する強心薬使用...
R1.07.20��>@;&-�#0 ( ,$�).
BGAICEJF �"�1%�O�"'�N+*
��2�=��8:���LHeart Failure with Reduced Ejection Fraction; HFrEFM
<�9?����!=pros/cons
clinical question 5347�7�63�
�/O� �
DKHO�$
•1
1 / m 8• LVEF=20% / 1• 1 g• 1 2 /
/ / 01 1
m
CQ������������ ��������������
� !��(LVEF)%)*���& LVEF ��
40 %�� LVEF&��#$���(Heart failure with reduced ejection fraction; HFrEF)
40 %350 % LVEF"����#$���(Heart failure with midrange ejection fraction; HFmrEF)
50 %�� LVEF&�$+$���(Heart failure with preserved ejection fraction; HFpEF)
40 %��(��' 40 %
��)
LVEF"��#$���(Heart failure with preserved ejection fraction, improved; HFpEF
improved($' heart failure with recovered EF; HFrecEF)
��4�������-,./,012017����2
U g Jt nC 0 . , D A 9 DC : D D: D D / CD 1 2A1 D D: .)( 2A1 D ,
:DDAC( AD D ) CC
• i u e ei UM TdpU I
• f UWim srj yU S I
• g f Tn Wo Pa wM I
• hlg f Tn U W wWc T I
����
T JSI U PMUC 0 . , D A 9 DC : D D: D D / CD 1 2A1 D D: .)( 2A1 D ,
:DDAC( AD D ) CC
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Ø � ��� �������� BNP�����������������������!
J Am Coll Cardiol. 2005 Jul 5;46(1):57-64.
������������������
!"�%" �P>qox�o��2017�,O8�
+�r�t
p{w�t�|�
�L�(sBP<90 mmHg)i�65e'Mm/_k#Eaf�
)Re��iL��.�12�:e,��3?H�4FeC*m@?b^`�A0Se� KeBUG(�mD&^`hJW
�b C
�}s~�u�iPDE�T�KeBUG(�f�βQ-KZ�
65m�X�L�d��^`Wk\bZ$�]lk� �D&^`hJW�
�b C
� Kf�"eN7Yj�L�i�65eI�=9m�^`Wk� ��df+�]lcW � A
.�K(z�nx�y��Z+�)f�e� Km�;^`h,�
^cW �"s�vrd�^`�L��.iH�65 C*e@?a�;mD&^`hJW�
�b B
2016 ESC Guidelines
+��fV[cW�;^`hA0Sd<gk
Eur J Heart Fail. 2016 Aug;18(8):891-975.
• P E• D• C
• 3 D D•
) -C) (-
) (-
��� ������������
Heart. 2001 Jul; 86(1): 81����
• ( 12• ( 12 12
• - )+
Am J Med Sci. 1987 Oct;294(4):244-8..
5< /
�����! �!��2�: 468.
Heart. 2001 Jul; 86(1): 81����
����������������
•'+2�
�(�
• 6!/2%������-'2�
� �
• �.&0 1
�����
• 6
%,"3�*�J Am Coll Cardiol. 1986 May;7(5):1107-13.
• 6%.)#$��(��
Intensive Care Med. 2012 Mar;38(3):359-67
���� ����
Intensive Care Med. 2012 Mar;38(3):359-67
Am Heart J. 1999 Jul;138(1 Pt 1):78-86.J Am Coll Cardiol. 2005 Jul 5;46(1):57-64.
Am Heart J. 2002 Dec;144(6):1102-8.
• ��������� ��1 2 D
1 /�) ( -
D ) ( -
) ( -
Am J Cardiol. 2007 Jan 22;99(2A):4A-23A
5 ��� Heart. 2001 Jul; 86(1): 81����
��� ������������
�������� ����
•5.!4�*&
'0� EInt J Cardiol. 2016 Nov 1;222:1003-1011
• -�6�"26�����3� �(���# �
Int J Cardiol. 2016 Nov 1;222:1003-1011
• H
'�/��(����1�
JAMA. 2013 Dec 18;310(23):2533-43.
• .7)� +$,�
8%����(FCirc Heart Fail. 2016 Aug;9(8). pii: e002593.
/• E )
E•
D
P
E
��& ����� �!"�#$2017����%
Heart. 2001 Jul; 86(1): 81����
• D ) P (
���������������
P 6
• P
/0,
J Am Coll Cardiol. 2003;41(6):997.
• E/
JAMA. 2002 Mar 27;287(12):1541-7.
• D PE
D
J Cardiol Jpn Ed 2008; 1: 148–154
) A TD
• P+(
• EK
(
��������)Heart. 2001 Jul; 86(1): 81 ����
��� ������������
Wilson S Colucci, MD. Inotropic agents in heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (Accessed on July 12, 2019.)
���� � ()���� ����
• B c/&@# ')�/7-A %1
,Circulation. 2000 Oct 31;102(18):2222-7.J Am Coll Cardiol. 2000 Nov 15;36(6):1903-12.Circulation. 2003 Jan 7;107(1):81-6.
• B c /823" ��� +:? %1 ,
Eur Heart J. 2002 Sep;23(18):1422-32.
• BN
5(#�80;6 *9.�+:?�3�,
JACC Heart Fail. 2013 Apr;1(2):103-11.
• BP
+:?�5$���,JAMA. 2007 May 2;297(17):1883-91.• !,4<
���� ���=>,Eur J Heart Fail. 2009 Mar;11(3):304-11
���� -()���� ����
• 14
cHeart. 1996;76(3):223.
•2Heart. 1996;76(3):223.
•1 c
1 2Circ J. 2002 Feb;66(2):149-57.
• /2 1024/2
/2 -2 P-2 5
• : 5 T a5 N s
a C+ ) (
�����7
• K ; C A5eC
Heart. 2001 Jul; 86(1): 81����
��� ������������
�� �������� "92570(%3)��� %4!-�%/'������6+,8��:
���������� �� ��2017����Eur J Heart Fail. 2016 Aug;18(8):891-975.
�������&#
������"9��:�� $�* %�.�1��
/��$-#&��(��������,*�"�����0��)!���+����$-�%� .��'���
Leonard I Ganz, MD. Control of ventricular rate in atrial fibrillation: Pharmacologic therapy Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.https://www.uptodate.com (Accessed on July 12, 2019.)
����� 5+$�� ���
• E
,' ���(1!8�/"
N Engl J Med. 1997 Feb 20;336(8):525-33.
• E F
67+�*��������3�
• E )48��#:�����������Eur Heart J. 2015 Jul 21;36(28):1831-8.BMJ. 2015 Aug 30;351:h4451
Leonard I Ganz, MD. Control of ventricular rate in atrial fibrillation: Pharmacologic therapy Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.https://www.uptodate.com (Accessed on July 12, 2019.)
• ������.- H0%29�#&
J Am Coll Cardiol. 2019 Aug 6;74(5):617-627.
• D E
N Engl J Med. 1991 Nov 21; 325(21): 1468-75.Circulation. 1990 Sep;82(3):774-80.
• .Lancet. 1990 Jul 7;336(8706):1-6.
()
A C3 . - 0 2 . 4 (( )
k col b V p
F D 3
F 3
F
3 po
P A E 3H E c 3
D c p /( )
J 97 :7 = ; ;
•1
16 ������ 1
u H6
u r E F 1
• H 11
• 5
u a,
Ø Teh /��������
g
u Te c